Longeveron Inc. (LGVN) Financial Statements (2025 and earlier)
Company Profile
Business Address |
1951 NW 7TH AVENUE MIAMI, FL 33136 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
---|---|---|---|---|---|---|
ASSETS | ||||||
Current Assets | ||||||
Cash, cash equivalents, and short-term investments, including: | 5,361 | 19,658 | 9,963 | |||
Cash and cash equivalents | 4,949 | 10,503 | 25,658 | |||
Short-term investments | 412 | 9,155 | 9,471 | |||
Other undisclosed cash, cash equivalents, and short-term investments | (25,166) | |||||
Receivables | 111 | 436 | 55 | |||
Deferred costs | 200 | |||||
Other undisclosed current assets | 376 | 186 | 25,162 | |||
Total current assets: | 5,848 | 20,280 | 35,380 | |||
Noncurrent Assets | ||||||
Operating lease, right-of-use asset | 1,221 | 1,531 | ||||
Property, plant and equipment | 2,529 | 2,949 | 3,062 | |||
Intangible assets, net (including goodwill) | 2,287 | 2,409 | 2,334 | |||
Intangible assets, net (excluding goodwill) | 2,287 | 2,409 | 2,334 | |||
Other noncurrent assets | 193 | |||||
Other undisclosed noncurrent assets | 244 | 1,990 | ||||
Total noncurrent assets: | 6,230 | 7,133 | 7,386 | |||
TOTAL ASSETS: | 12,078 | 27,413 | 42,766 | |||
LIABILITIES AND EQUITY | ||||||
Liabilities | ||||||
Current Liabilities | ||||||
Accounts payable and accrued liabilities | 2,790 | 650 | 1,972 | |||
Accounts payable | 638 | 645 | ||||
Accrued liabilities | 2,152 | 650 | 1,327 | |||
Deferred revenue | 506 | 506 | ||||
Debt | 2,315 | |||||
Other undisclosed current liabilities | 593 | 1,398 | 736 | |||
Total current liabilities: | 3,889 | 4,869 | 2,708 | |||
Noncurrent Liabilities | ||||||
Liabilities, other than long-term debt | 1,448 | |||||
Other liabilities | ||||||
Operating lease, liability | 1,448 | |||||
Other undisclosed noncurrent liabilities | 2,041 | 2,605 | ||||
Total noncurrent liabilities: | 1,448 | 2,041 | 2,605 | |||
Total liabilities: | 5,337 | 6,910 | 5,313 | |||
Equity | ||||||
Equity, attributable to parent, including: | 6,741 | 20,503 | 37,453 | |||
Common stock | 6 | 5 | ||||
Treasury stock, value | (100) | (100) | ||||
Additional paid in capital | 91,800 | 83,712 | 81,470 | |||
Accumulated other comprehensive loss | (357) | |||||
Accumulated deficit | (84,984) | (62,773) | (43,938) | |||
Stockholders' equity note, subscriptions receivable | (100) | |||||
Other undisclosed equity, attributable to parent | 25 | 15 | 16 | |||
Total equity: | 6,741 | 20,503 | 37,453 | |||
TOTAL LIABILITIES AND EQUITY: | 12,078 | 27,413 | 42,766 |
Income Statement (P&L) ($ in thousands)
9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
---|---|---|---|---|---|
Revenues | 709 | 1,222 | 1,306 | ||
Other income | 300 | 115 | |||
Cost of revenue | (488) | (725) | (716) | ||
Gross profit: | 221 | 497 | 590 | ||
Operating expenses | (21,250) | (18,540) | (18,046) | ||
Operating loss: | (21,029) | (18,043) | (17,456) | ||
Nonoperating income (expense) | (384) | (792) | 411 | ||
Other nonoperating income (expense) | (377) | (792) | 411 | ||
Interest and debt expense | (1,398) | (4) | |||
Other undisclosed loss from continuing operations before equity method investments, income taxes | |||||
Loss from continuing operations before income taxes: | (21,413) | (20,233) | (17,049) | ||
Other undisclosed income from continuing operations | 1,398 | 4 | |||
Loss from continuing operations: | (21,413) | (18,835) | (17,045) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (17,045) | |
Net loss: | (21,413) | (18,835) | (17,045) | ||
Other undisclosed net loss attributable to parent | |||||
Net loss attributable to parent: | (21,413) | (18,835) | (17,045) | ||
Preferred stock dividends and other adjustments | |||||
Other undisclosed net loss available to common stockholders, basic | (798) | ||||
Net loss available to common stockholders, diluted: | (22,211) | (18,835) | (17,045) |
Comprehensive Income ($ in thousands)
9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
---|---|---|---|---|---|
Net loss: | (21,413) | (18,835) | (17,045) | ||
Comprehensive loss: | (21,413) | (18,835) | (17,045) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 357 | ||||
Comprehensive loss, net of tax, attributable to parent: | (21,413) | (18,478) | (17,045) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.